Opinion|Videos|January 15, 2025
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients
A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly review recent ESMO guideline updates for the frontline management of patients with IGHV-unmutated or mutated and no TP53 mutation and discuss associated implications.
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
FDA Flashback: Breast Cancer Decisions and News From June 2026
5